Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2026)
Inhibikase Therapeutics (IKT) reported Other Accumulated Expenses of $109350.0 for Q1 2026, down 14.37% year-over-year from $127703.0 in Q1 2025, and down 48.64% quarter-over-quarter from $212927.0 in Q4 2025.
Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 7 years of Other Accumulated Expenses data on file, last reported at $109350.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $109350.0, down 14.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $109350.0 (down 14.37% YoY), and the FY2025 annual result was $212927.0, up 162.87% from the prior year.
- Other Accumulated Expenses fell to $109350.0 in Q1 2026 per IKT's latest filing, from $212927.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $212927.0 in Q4 2025 and troughed at $100.0 in Q1 2023.
- A 5-year average of $55688.5 and a median of $25561.0 in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses sank 99.69% in 2023, then surged 25461.0% in 2024.
- A 5-year view of Other Accumulated Expenses shows it stood at $9920.0 in 2022, then jumped by 936.46% to $102817.0 in 2023, then declined by 21.22% to $81000.0 in 2024, then jumped by 162.87% to $212927.0 in 2025, then tumbled by 48.64% to $109350.0 in 2026.
- Business Quant data shows IKT's Other Accumulated Expenses at $109350.0 in Q1 2026, $212927.0 in Q4 2025, and $116166.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109,350.00 |
| Dec 31, 2025 | 212,927.00 |
| Sep 30, 2025 | 116,166.00 |
| Jun 30, 2025 | 74,316.00 |
| Mar 31, 2025 | 127,703.00 |
| Dec 31, 2024 | 81,000.00 |
| Sep 30, 2024 | 13,050.00 |
| Jun 30, 2024 | 10,931.00 |
| Mar 31, 2024 | 25,561.00 |
| Dec 31, 2023 | 102,817.00 |
| Sep 30, 2023 | 100.00 |
| Jun 30, 2023 | 1,725.00 |
| Mar 31, 2023 | 100.00 |
| Dec 31, 2022 | 9,920.00 |
| Sep 30, 2022 | 32,671.00 |
| Jun 30, 2022 | 10,630.00 |
| Mar 31, 2022 | 17,737.00 |
| Dec 31, 2021 | 5,127.00 |
| Sep 30, 2021 | 11,518.00 |
| Jun 30, 2021 | 5,497.00 |